Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Twin study aims to unlock secrets of metabolic syndrome and liver disease

NCT ID NCT07181018

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study follows 1,500 twins aged 15-44 in Poland over 5 years to learn how metabolic syndrome and related liver problems develop. Researchers will look at genetics, environment, and gut bacteria. Some twins will get an educational program to encourage healthy changes, while their co-twin serves as a control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
educational intervention
What this could lead to
If successful, this could reveal key risk factors and genetic influences for metabolic syndrome and liver disease, pointing toward better prevention strategies.
What could go wrong
This is an observational study with an educational component, not a treatment trial. Results may not apply to non-twin populations, and the intervention's impact may be limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Sep 2033

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population comprises Polish twin individuals aged 15-44 years, who have provided informed consent, have a living co-twin, and present a positive family history (first- or second-degree relatives) of metabolic syndrome, its related comorbidities, or common complications.

Ages

15 to 44 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1\. Age between 15 and 44 years. 2. Provision of informed consent to participate in the study. 3. Twin with a living co-twin. 4. Positive family history in first- and second-degree relatives of metabolic syndrome (MS), associated diseases, or the most common complications of the syndrome. \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Exclusion Criteria Permanent exclusion criteria: 1. Co-twin does not consent to participate in the study. 2. Inability to obtain medical history of biological family members. 3. Presence of advanced liver fibrosis, cirrhosis, or liver cancer. 4. Known liver genetic disorders, autoimmune hepatitis, celiac disease, hemochromatosis, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), cystic fibrosis, or Wilson's disease. 5. Current or chronic alcohol consumption \>20 g of ethanol/day in women and \>30 g/day in men. 6. Short bowel syndrome. 7. Cyanotic congenital heart defect. 8. Myasthenia. 9. Central nervous system degenerative diseases such as Alzheimer's disease, Parkinson's disease, or Huntington's disease. 10. Storage diseases involving the liver. 11. Active malignant neoplasm undergoing treatment (excluding non-melanoma skin cancers and melanoma treated non-pharmacologically). 12. Chronic kidney disease requiring renal replacement therapy. 13. Status post organ or tissue transplantation requiring immunosuppression. 14. Pituitary, hypothalamic, or adrenal hyperfunction/hypofunction requiring hormone supplementation. 15. Addiction to psychoactive substances or drugs. 16. Other severe and incurable diseases that, in the investigator's opinion, constitute a permanent contraindication for participation in the study. 17. Lack of cooperation by the volunteer during the visit to the Research Center. \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Temporary exclusion criteria (after resolution, the volunteer may be enrolled): 1. Acute infection, low-grade fever or fever, or use of antibiotics at the time of recruitment or prior to the visit at the Research Center - inclusion possible after 6 weeks. 2. Any vaccination within the past 6 weeks. 3. Pregnancy and up to 6 months postpartum. 4. 3 months after the natural cessation of breastfeeding. 5. 3 months after surgery (does not apply to minor surgical procedures). 6. Untreated hyperthyroidism or hypothyroidism - inclusion possible 3 months after achieving euthyroidism. 7. Significant weight loss or gain in the past 3 months (\>10% of initial body weight) - inclusion possible 3 months after weight stabilization. 8. 6 months after discontinuation of temporary parenteral or enteral nutrition via feeding tube. 9. 12 months after bariatric surgery. 10. Systemic treatment with steroids, chemotherapy, immunosuppressive drugs, or biological therapy known to be hepatotoxic or potentially inducing abnormalities found in MS - inclusion possible at least 3 months after completing therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Uniwersytecki Szpital Kliniczny

    RECRUITING

    Poznan, Wielkopolska, 60-355, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.